Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2026
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867015698977390592 |
|---|---|
| author | Xiaoxiao Fan Chenxi Wei Minjun Rong Shengnan Wang Jiaying Wang Xiaohan Wang Xiao Han Xue Meng |
| author_facet | Xiaoxiao Fan Chenxi Wei Minjun Rong Shengnan Wang Jiaying Wang Xiaohan Wang Xiao Han Xue Meng Xiaoxiao Fan Chenxi Wei Minjun Rong Shengnan Wang Jiaying Wang Xiaohan Wang Xiao Han Xue Meng |
| collection | Wiley Open Access |
| contents | Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors Xiaoxiao Fan Chenxi Wei Minjun Rong Shengnan Wang Jiaying Wang Xiaohan Wang Xiao Han Xue Meng International Journal of Cancer Abstract PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in NSCLC patients without driver gene mutations. However, its significance in patients with driver gene‐positive tumors remains unclear. This study analyzed 273 patients with stage IV non‐small cell lung cancer harboring driver gene mutations. All patients had PD‐L1 expression levels ≥10%. The effect of PD‐L1 expression on progression‐free survival (PFS) and overall survival (OS) was assessed. Among the 273 patients with driver gene‐positive NSCLC, 127 had a PD‐L1 tumor proportion score (TPS) of 10–49%, and 146 had TPS ≥50%. Patients in the TPS 10%–49% group had significantly better median PFS and OS compared to those in the TPS ≥50% group ( p = 0.0008 and p = 0.0009, respectively). In the realm of targeted therapy, patients who received first‐line tyrosine kinase inhibitors (TKIs) showed superior outcomes in the TPS 10–49% group compared to the TPS ≥50% group in terms of both median PFS (30.8 months vs. 13.9 months, p = .0001) and OS (44.8 months vs. 26.3 months, p = .0006). Regarding immunotherapy, PD‐L1 expression level was not significantly associated with treatment efficacy. However, in patients with KRAS mutations, those who received first‐line immunotherapy exhibited better median PFS and OS ( p <.0001 for both). Notably, among patients with high PD‐L1 expression, no statistically significant clinical benefit was observed. In NSCLC patients with driver gene mutations, PD‐L1 expression is associated with the efficacy of targeted therapy but is not predictive of response to immunotherapy. 10.1002/ijc.70413 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/ijc.70413 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_ijc_70413 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2026 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors Xiaoxiao Fan Chenxi Wei Minjun Rong Shengnan Wang Jiaying Wang Xiaohan Wang Xiao Han Xue Meng International Journal of Cancer Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors Xiaoxiao Fan Chenxi Wei Minjun Rong Shengnan Wang Jiaying Wang Xiaohan Wang Xiao Han Xue Meng International Journal of Cancer Abstract PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in NSCLC patients without driver gene mutations. However, its significance in patients with driver gene‐positive tumors remains unclear. This study analyzed 273 patients with stage IV non‐small cell lung cancer harboring driver gene mutations. All patients had PD‐L1 expression levels ≥10%. The effect of PD‐L1 expression on progression‐free survival (PFS) and overall survival (OS) was assessed. Among the 273 patients with driver gene‐positive NSCLC, 127 had a PD‐L1 tumor proportion score (TPS) of 10–49%, and 146 had TPS ≥50%. Patients in the TPS 10%–49% group had significantly better median PFS and OS compared to those in the TPS ≥50% group ( p = 0.0008 and p = 0.0009, respectively). In the realm of targeted therapy, patients who received first‐line tyrosine kinase inhibitors (TKIs) showed superior outcomes in the TPS 10–49% group compared to the TPS ≥50% group in terms of both median PFS (30.8 months vs. 13.9 months, p = .0001) and OS (44.8 months vs. 26.3 months, p = .0006). Regarding immunotherapy, PD‐L1 expression level was not significantly associated with treatment efficacy. However, in patients with KRAS mutations, those who received first‐line immunotherapy exhibited better median PFS and OS ( p <.0001 for both). Notably, among patients with high PD‐L1 expression, no statistically significant clinical benefit was observed. In NSCLC patients with driver gene mutations, PD‐L1 expression is associated with the efficacy of targeted therapy but is not predictive of response to immunotherapy. 10.1002/ijc.70413 http://creativecommons.org/licenses/by/4.0/ |
| title | Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors |
| topic | International Journal of Cancer |
| url | https://onlinelibrary.wiley.com/doi/10.1002/ijc.70413 |